Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice

키워드

참고문헌 (57)

1. Kyle RA, "Multiple myeloma", N Engl J Med, 351, pp.1860~1873 (2004)
2. International Myeloma Working Group, "Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group", Br J Haematol, 121, pp.749~757 (2003)
3. Antonio Palumbo, "Diagnosis and therapy of multiple myeloma", The Korean Journal of Internal Medicine, 28(3), pp.263~273 (2013), 대한내과학회[DOI]
4. Jeong-Eun Yi, "Association between left ventricular function and paraprotein type in patients with multiple myeloma", The Korean Journal of Internal Medicine (2016), Korean Association of Internal Medicine[DOI]
5. Attal M, "A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome", N Engl J Med, 335, pp.91~97 (1996)
6. Attal M, "Single versus double autologous stem-cell transplantation for multiple myeloma", N Engl J Med, 349, pp.2495~2502 (2003)
7. Gentile M, "Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients", Expert Opin Pharmacother, 15, pp.1315~1320 (2014)
8. Cavo M, "Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma", Blood, 120, pp.9~19 (2012)
9. Usmani SZ, "Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured?", Leukemia, 27, pp.226~232 (2013)
10. Cavo M, "Role of consolidation therapy in transplant eligible multiple myeloma patients", Semin Oncol, 40, pp.610~617 (2013)
11. McCarthy PL, "The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients", Expert Rev Hematol, 7, pp.55~66 (2014)
12. Ludwig H, "IMWG consensus on maintenance therapy in multiple myeloma", Blood, 119, pp.3003~3015 (2012)
13. Mohty M, "Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?", Bone Marrow Transplant, 50, pp.1024~1029 (2015)
14. Cavo M, "Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma", Blood, 106, pp.35~39 (2005)
15. Rajkumar SV, "Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group", J Clin Oncol, 24, pp.431~436 (2006)
16. Harousseau JL, "Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01phase III trial", J Clin Oncol, 28, pp.4621~4629 (2010)
17. Lokhorst HM, "A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma", Blood, 115, pp.1113~1120 (2010)
18. Morgan GJ, "Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results", Haematologica, 97, pp.442~450 (2012)
19. Barlogie B, "Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma", Cancer, 113, pp.355~359 (2008)
20. Rawstron AC, "Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study", J Clin Oncol, 31, pp.2540~2547 (2013)
21. Mellqvist UH, "Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial", Blood, 121, pp.4647~4654 (2013)
22. Ladetto M, "Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma", J Clin Oncol, 28, pp.2077~2084 (2010)
23. Attal M, "Lenalidomide maintenance after stem-cell transplantation for multiple myeloma", N Engl J Med, 366, pp.1782~1791 (2012)
24. Roussel M, "Frontline transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome", J Clin Oncol, 32, pp.2712~2717 (2014)
25. Leleu X, "Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma", Leukemia, 27, pp.2242~2244 (2013)
26. McCarthy PL, "Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients", Hematology Am Soc Hematol Educ Program, 2013, pp.496~503 (2013)
27. Attal M, "Maintenance therapy with thalidomide improves survival in patients with multiple myeloma", Blood, 108, pp.3289~3294 (2006)
28. Barlogie B, "Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities", Blood, 112, pp.3115~3121 (2008)
29. Morgan GJ, "The role of maintenance thalidomide therapy in multiple myeloma:MRC myeloma IX results and meta-analysis", Blood, 119, pp.7~15 (2012)
30. Stewart AK, "A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial", Blood, 121, pp.1517~1523 (2013)
31. Spencer A, "Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure", J Clin Oncol, 27, pp.1788~1793 (2009)
32. Maiolino A, "Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma", Am J Hematol, 87, pp.948~952 (2012)
33. Sonneveld P, "Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65", GMMG-HD4trial, 2012, pp.30, 2946~2955
34. Rosinol L, "Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma:a randomized phase 3 PETHEMA", GEM study, 2012, pp.120, 1589~1596
35. McCarthy PL, "Lenalidomide after stem-cell transplantation for multiple myeloma", N Engl J Med, 366, pp.1770~1781 (2012)
36. Palumbo A, "Autologous transplantation and maintenance therapy in multiple myeloma", N Engl J Med, 371, pp.895~905 (2014)
37. Gay F, "Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma:a randomised, multicentre, phase 3 trial", Lancet Oncol, 16, pp.1617~1629 (2015)
38. Lee HS, "The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea", Ann Hematol, 95, pp.911~919 (2016)
39. Palumbo A, "Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial", Blood, 112, pp.3107~3114 (2008)
40. Wijermans P, "Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study", J Clin Oncol, 28, pp.3160~3166 (2010)
41. Waage A, "Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma", Blood, 116, pp.1405~1412 (2010)
42. Mateos MV, "Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial", Lancet Oncol, 11, pp.934~941 (2010)
43. Palumbo A, "Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival", J Clin Oncol, 32, pp.634~640 (2014)
44. Palumbo A, "Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial", J Clin Oncol, 28, pp.5101~5109 (2010)
45. Niesvizky R, "Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens", J Clin Oncol, 33, pp.3921~3929 (2015)
46. Palumbo A, "Continuous lenalidomide treatment for newly diagnosed multiple myeloma", N Engl J Med, 366, pp.1759~1769 (2012)
47. Benboubker L, "Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma", N Engl J Med, 371, pp.906~917 (2014)
48. Zweegman S, "Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma", Blood, 127, pp.1109~1116 (2016)
49. Facon T, "Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial", Lancet, 370, pp.1209~1218 (2007)
50. Hulin C, "Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01", 01 trial, 2009, pp.27, 3664~3670
51. Beksac M, "Addition of thalidomide to oral melphalan", prednisone in patients with multiple myeloma not eligible for transplantation:results of a randomized trial from the Turkish Myeloma Study Group, 2011, pp.86, 16~22
52. Kagoya Y, "Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis", Leuk Res, 36, pp.1016~1021 (2012)
53. Moreau P, "Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study", Lancet Oncol, 12, pp.431~440 (2011)
54. Palumbo A, "Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data", Lancet Oncol, 15, pp.333~342 (2014)
55. Paiva B, "Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation", Blood, 112, pp.4017~4023 (2008)
56. Chng WJ, "IMWG consensus on risk stratification in multiple myeloma", Leukemia, 28, pp.269~277 (2014)
57. Paiva B, "High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma", Blood, 119, pp.687~691 (2012)

관련 논문AI추천